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 Changes in infant fecal microbiome correlates with the presence of triclosan in mother's breast milk.
 TCS is detected in breast milk from women who use triclosan-containing personal care products daily.
 The method to extract triclosan from breast milk is improved by adding salt and water.
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Triclosan is frequently used for its antimicrobial properties and has been detected in human serum,
urine, and breast milk. Animal and molecular studies have shown that triclosan exerts a wide range of
adverse health effects at both high (ppm) and low (ppb) concentrations. Since triclosan is of growing
concern to human and environmental health, there is a need to improve extraction procedures and to
study additional effects from triclosan exposure. In this study, we have improved triclosan extraction
from breast milk by using salt (MgSO4) to reduce emulsion formation and increase water polarity and
water (~80%) to enhance the overall extraction efﬁciency (~3.5 fold). This extraction method was applied
to breast milk samples collected from donors who i) recorded their use of triclosan-containing personal
care products and ii) provided matching infant stool samples. Of the participants who had detectable
amounts of triclosan in their breast milk, nine (75%) of them reported daily use of triclosan-containing
personal care products. Levels of triclosan in breast milk were compared to the donor's infant's fecal
microbiome. We found that the bacterial diversity in the fecal microbiome of the infants exposed to
breast milk with detectable triclosan levels differed compared to their peers exposed to milk containing
non-detectable amounts. This ﬁnding implies that exogenous chemicals are impacting microbiome
diversity.
Published by Elsevier Ltd.

Handling Editor:
Keywords:
Triclosan
Breast milk
Fecal microbiome
Infant
Personal care products

1. Introduction
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2
Present address: Chemistry Department, Carleton University, Ontario, Canada.
3
Present address: Department of Chemistry, Umeå University, 901 87 Umeå,
Sweden.

Triclosan (TCS) is typical of a growing list of chemicals whose
exposure was initially deemed insigniﬁcant but where massive
commercial success lead to concerns about their impact on humans
and the environment. Recent reviews on TCS recount numerous
health effects ranging from endocrine-disruption to uncoupling
mitochondria and interfering with ion channels (Olaniyan et al.,
2016; Yueh and Tukey, 2016; Ruszkiewicz et al., 2017; Weatherly
and Gosse, 2017). Most importantly, many of the cellular mechanisms are disrupted at doses around the ppm (mg mL1) level and
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lower. For reference, dermal exposure can be as high as
3000 mg mL1 since products can be formulated to contain up to
0.3%. Although the FDA banned TCS from certain wash products
(namely hand soap and body wash) in 2016 (FDA, 2016) and hospital products by the end of 2018 (FDA, 2017), it is permissible to
have TCS in toothpastes, cosmetics, clothes, toys, and other products. Therefore, human exposure to TCS remains dramatically high
at this time.
TCS was reported in breast milk at concentrations ranging from
non-detectable to 63 ng mL1 (ppb) (assuming ~3% lipids when
reported per lipid weight) (Adolfsson-Erici et al., 2002; Allmyr et al.,
2006a; Dayan, 2007; Ye et al., 2008; Toms et al., 2011; Wang et al.,
2011; Azzouz et al., 2016). In the US, few studies have analyzed TCS
in breast milk and none have correlated these levels with TCScontaining personal care product (PCP) use. A study from Sweden
that demonstrated that TCS concentrations in breast milk correlated with exposure to PCPs (Allmyr et al., 2006a), with maximum
levels of 1 ng mL1 (ppb). Samples from the US population far
exceed these values, but without identiﬁed sources of exposure
(Dayan, 2007). The major fraction of TCS is eliminated from the
body within 24 h of a single exposure (Sandborgh-Englund et al.,
2006). However, exposure from toothpaste is usually 1e3 times
per day and exposure from hand soap is typically 3e6 times per
day.
TCS is frequently marketed in products for its antimicrobial
properties; at low doses it is bacteriostatic and at higher doses it is
bacteriocidal and active against a wide range of both Gramnegative and Gram-positive bacteria (Russell, 2004). Altered gut
bacterial community structures were observed in animal models
challenged via an oral route at ppm levels (Gaulke et al., 2016; Gao
et al., 2017) and ﬁsh submerged in water at ppb levels (Narrowe
et al., 2015). However, human studies are contradictory with a
small cross-over human study failing to detect differences between
time periods with and without TCS exposure (Poole et al., 2016),
while another study found perturbation of adult but not infant gut
microbiome in households randomly assigned to use TCS containing products compared to those not using TCS products (Ribado
et al., 2017). The impact of TCS in breast milk on the infant microbiome remains unstudied.
Given that TCS was shown to modify microbiome diversity and
that TCS is present in breast milk, we sought to test the hypothesis
that TCS in breast milk correlates with changes in the infant
microbiome. To accomplish this, we examined a cohort of US
lactating women and documented their daily use of TCS-containing
PCPs. We assessed women's exposure to TCS-containing PCPs by
collecting survey information and by measuring TCS in their breast
milk samples. We then used the results to investigate the effect on
the fecal microbiome of infants whose mothers' breast milk contained TCS in detectable vs. non-detectable concentrations. We
explicitly evaluated sample handling techniques with the goal of
reducing the formation of emulsions, which commonly plagues
human milk extraction procedures, as well as improving TCS recovery by employing a TCS 14C radiotracer.

observational study, the UC Davis Lactation Study (initiated in
January 2008 and ended active enrollment in February 2015)
(Smilowitz et al., 2013). Brieﬂy, participants from the larger study
who expressed interest in allowing their samples to be used for
further studies were re-contacted for participation in this pilot
study. Those who provided informed consent to participate in this
pilot, had completed the survey and provided fecal samples were
included. Participants from Cohort 1 completed one recall survey
and their previously collected, banked samples were analyzed.
These participants were asked to recall their use of speciﬁc PCP
during pregnancy and throughout the ﬁrst year of lactation when
they were enrolled in the parent study. Cohort 2 participants
completed surveys around the time that the breast milk and infant
stool samples were collected. Forty-ﬁve women (34 from Cohort 1
and 11 from Cohort 2) completed the TCS study. The UC Davis
Institutional Review Board approved all aspects of the study, which
was conducted in accordance with the Declaration of Helsinki
regarding human experimentation, and informed consent was
obtained from all subjects. This trial was registered on clinicaltrials.
gov (ClinicalTrials.gov Identiﬁer: NCT01817127).

2. Materials and methods

To determine the recovery of TCS in breast milk, 14C-TCS (Moravek Biochemical, Brea, CA) was used. Samples of breast milk (1 mL)
were spiked with 14C-TCS (5 mL) resulting in approximately 6000
dcm per sample. Duplicate samples of each solvent type (isopropanol, acetonitrile, methanol, ethyl acetate, methyl-tert-butyl
ether (MTBE), and hexane) were extracted in triplicate with 1 mL of
solvent. Samples were inverted 30 times and then centrifuged to
reduce any emulsions that formed. The distribution of radioactivity
was measured by separating the extract phase from the rafﬁnate
phase. For the water-immiscible solvents, the organic extract phase
was separated from the rafﬁnate (aqueous phase often containing

All reagents were of analytical grade and purchased from MilliporeSigma (St. Louis, MO) or Fisher Scientiﬁc (Waltham, MA),
unless otherwise noted.
2.1. Participants
Participants and their healthy term (>37 weeks gestation) infants were recruited to participate in this TCS Pilot Study from May
2013 until February 2015 from two cohorts of the one-year parent

2.2. Survey design
The survey was part of a broader metadata collection protocol
that has been successfully used to examine various lactation interventions and outcomes. The speciﬁc subset of the survey
devoted to TCS took advantage of the commitment and training of
mothers to the broader study. The survey was comprised of an
image of various TCS-containing products, listed by categories,
along with its corresponding name (Figure S1). The products were
identiﬁed by searching through the US Department of Health and
Human Services' Household Products Database. Then, participants
were asked to ﬁll in a chart of how often a particular product was
used, assessing daily (expressed as 1x/day, 2e5 x/day, or as multiple times a day), weekly (expressed as 1x/week or multiple times
each week), monthly (expressed as 1x/month or a few times each
month) or no use. The discrepancy in the terms was due to the
changing in wording on the surveys administered to each cohort.
Because of this, these terms listed were aggregated and recorded as
the corresponding ‘daily/weekly/monthly’ designation.
2.3. Sample collection
A total of 45 breast milk and matched infant stool samples
collected between 8 and 13 weeks postpartum were analyzed for
TCS and fecal microbiome content, respectively. Details of breast
milk and infant stool sample collections are reported elsewhere
(Lewis et al., 2015). Breast milk samples were collected prior to the
conception of this pilot project and so no special instructions were
given to individuals to minimize exogenous chemical
contamination.
2.4. Radioactivity studies
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precipitated proteins) and pooled. For the water-miscible solvents,
the top aqueous phase was separated from the precipitated rafﬁnate phase and pooled. Scintillator solution (15 mL) was added to
each fraction to correct for quench, which accounted for the variable volumes in each fraction, and analyzed by a liquid scintillation
counter (Perkin Elmer, Waltham, CA). Blank vials containing just
the 14C-TCS spike were measured alongside the samples to determine full recovery of the radiotracer. We further explored 14C-TCS
partitioning by testing for radioactivity in 0.5 mL breast milk
samples spiked with 14C-TCS (5 mL) and then treating the sample
with i) acid (H2SO4, 9 M ﬁnal in sample), then extracting with
hexane:acetone (9:1), and ii) acetonitrile (1 mL) and adding varying
amounts (in triplicate) of deionized water (0, 0.5 and 4 mL). Each
sample was then extracted in triplicate with 1 mL hexane by
inverting the vials 30 times. Organic extracts were pooled and the
distribution of radioactivity was measured as described previously.
2.5. Sample preparation
Extraction of TCS from breast milk was completed similar to a
previously described method (Allmyr et al., 2006a) with modiﬁcations based on the optimized protocol established in the radioactivity studies described in section 2.4. One notable modiﬁcation
included not subjecting the sample to hydrolysis to cleave any
metabolic conjugates of TCS. This was omitted because previous
studies had observed that conjugated species of TCS are negligible
in breast milk (Ye et al., 2008; Toms et al., 2011), although present in
blood and urine. Another modiﬁcation was changing the derivatizing agent given the inadequate performance of the pentaﬂuorobenzoyl derivative, which was observed to cause low yields of
derivatized analyte and/or poor GC-MS peak shape (Allmyr et al.,
2006b). The ﬁnal modiﬁcation was the incorporation of the
extraction and partitioning step from the QuEChERS (quick, easy,
cheap, effective, rugged, and safe) method using an organic solvent
(acetonitrile) and salt (MgSO4) solution (Gonzalo-Lumbreras et al.,
2014).
The revised method was as follows: 10 ppm 13C-TCS (5 mL,
Cambridge Isotope Laboratories, Andover, MA) was spiked into
each breast milk sample (2 or 3 mL). Then, acetonitrile containing
1% acetic acid (6 mL) and anhydrous MgSO4 (2.1 g) were added. The
samples were vortexed and then centrifuged at 3000  g for 5 min.
The supernatant was collected, water (27 mL) was added and
extracted in triplicate with hexane (3 mL). Extraction involved
inverting the tubes 30 times and collecting the organic fractions. To
the pooled extract (9 mL), 1 M NaOH (3 mL) was added and
extracted by inversion 30 times. The hexane layer was discarded.
The aqueous phase was neutralized with 1 M HCl (6 mL) and
extracted in triplicate with hexane (3 mL) by 30 inversions. The
organic fractions were pooled and solvent was evaporated under
vacuum using a ScanVac system (Neutec Group, Farmingdale, NY)
until dryness. To generate the 6-point internal calibration curve,
native TCS in methanol and 13C-TCS were added to separate 1.5 mL
plastic vials and dried under a stream of nitrogen. To the dried
samples
and
standards,
N-methyl-N-(trimethylsilyl)triﬂuoroacetamide (MSTFA) (50 mL) was added as a derivatization
agent, heated at 37  C for 30 min and transferred to GC vials.
Detailed GC-MS parameters are given in the Supplemental Information section (S1.2).
2.6. Calibration standards and recovery experiments
To determine if the matrix had an impact on TCS detection,
matrix-matched calibration curves were assembled. Donor milk
from a person vigilant about avoiding known TCS-containing
products was provided as the standard breast milk material.
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Breast milk matrix was extracted as described in section 2.5, spiked
with varying concentrations of TCS (5e500 ng mL1) in triplicate,
and then derivatized. Blank water samples were also spiked in
triplicate with varying concentrations of TCS (n ¼ 3).
Recovery experiments were completed to determine adequate
TCS extraction efﬁciency. Standard breast milk material was spiked
with known TCS concentrations in triplicate and then extracted and
derivatized, with ﬁnal theoretical TCS concentrations equaling 5,
15, 30, and 100 ng mL1.
2.7. Microbiome analysis
All infant stool samples were extracted using a ZR Fecal DNA
MiniPrep kit (ZYMO, Irvine, CA, USA) and the V4 region of the 16S
rRNA gene was sequenced as in Lewis et al., (2015) (Lewis et al.,
2015). The resulting reads were merged using PEAR (Zhang et al.,
2014), demultiplexed using FASTX tools(Lab), primers were trimmed from reads using cutadapt (Martin, 2011), and then reads were
loaded into QIIME (Caporaso et al., 2010); QIIME defaults were used
except where follows: operational taxonomic unit (OTU) picking
 et al., 2014), the
was completed using the SWARM algorithm (Mahe
representative sequence set was chosen using the most abundant
read in each OTU, and the OTU table was ﬁltered to remove all OTUs
that only occurred in a single sample.
Only samples from infants whose mothers were enrolled in the
TCS study were included in this analysis. In addition, samples with
low read depth (less than 5000 reads) were excluded. After
excluding low read depth samples, the sample collected closest in
time to the breast milk sample used for TCS analysis was selected
for inclusion. If two samples were collected within the same
number of days of the TCS measurement, only the ﬁrst collected
sample was eligible for inclusion. Infants who received either
probiotics or antibiotics prior to the collection of the included
sample and all infants who had ever received formula prior to the
day of included stool sample collection were excluded. After exclusions, 31 infants remained, 10 with mothers who had detectable
concentrations of TCS in their milk and 21 with mothers who had
non-detectable concentrations of TCS.
Before beginning analysis, OTUs without any reads in any of the
included samples were excluded. Samples were rareﬁed to a read
depth of 5000 reads. Beta diversity was visualized based on
weighted, unweighted, and generalized UniFrac distance matrices
using non-metric multidimensional scaling (NMDS) in R (Chen,
2012; R Core Team, 2016; Oksanen et al., 2017). NMDS was
selected for ordinations because NMDS makes fewer assumptions
about the underlying data structure than more common ordination
methods such as principal coordinates analysis (McCune et al.,
2002). The number of dimensions for the NMDS plot was chosen
based on scree plots of stress (McCune et al., 2002). Differences in
beta-diversity based on all three UniFrac measures between infants
exposed to detectable amounts of TCS in breast milk were tested
using PERMANOVA as implemented in the vegan package of R after
checking for differences in dispersion, as unbalanced study design
combined with differences in dispersion may skew the results of
PERMANOVA (Anderson and Walsh, 2013; Oksanen et al., 2017).
Differences in alpha diversity between infants from the detectable
and non-detectable groups were compared using the Shannon Index and Chao1 with Kruskal-Wallis tests (Oksanen et al., 2017). The
Shannon Index considers both the richness and evenness of a
sample when calculating alpha diversity, while the Chao1 index
considers only richness. Because of large variation in library size
between samples we then used the linear discriminate analysis
effect size method or LEfSE method (Segata et al., 2011) on the
rareﬁed data to identify taxa that differed between the two groups.
Only differences at the genus level and above will be discussed
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Table 1
Distribution of reported types and frequency of exposures to triclosan-containing
personal care products. (*For simplicity, participants with a mixture of exposure
types and frequency are not presented. Only those with daily exposure to both
dermal and oral products are presented).

Daily
Weekly
Monthly
None

Dermal

Oral

Both

10
5
3
21

4
0
3
32

6
–*
–*
18

because of SWARMs tendency to split sequences means analysis at
the species level may not be accurate.
3. Results and discussion
3.1. Survey ﬁndings
Exposures to TCS-containing PCPs were self-reported by each
participant (Table 1). Exposure frequency was categorized as daily,
weekly, monthly, or none. Exposure types were categorized as
either dermal (indicated by products intended for dermal contact,
such as liquid hand soaps) or oral (indicated by products intended
for oral contact, such as toothpaste). Of the 45 participants, over
half (27 people; 60%) reported using at least one of the TCScontaining PCPs listed in the survey. The highest frequency of using TCS-containing PCPs was for the daily use of dermal products
(16; n ¼ 10 daily dermal only þ n ¼ 6 both), followed by the daily
use of oral products (10; n ¼ 4 daily oral only þ n ¼ 6 both), which is
expected given the intrinsic utility of PCPs. In all, 20 (44%) participants reported using at least one TCS-containing PCP on a daily
basis, 6 of which used at least one oral and one dermal product
daily.
3.2. TCS detection in breast milk
3.2.1. Radioactivity partitioning of 14C-TCS
With any chemical extraction, the more steps involved, the more
opportunities to reduce analyte recovery. One tool to evaluate
different steps in the procedure is to use radioactively-labeled
target material and detect both the extract and the rafﬁnate
portion of the sample. In our effort to select an ideal solvent, we
conducted preliminary partitioning experiments using 14C-TCS. By
utilizing radioactivity, we were able to assess various stages of our
extraction procedures without having to complete full clean-ups of

the samples, nor rely on estimates of recovery, since all of the
starting material is measured. Using this method, six different
solvents were tested, three water-miscible (acetonitrile, isopropanol and methanol) and three water-immiscible (ethyl acetate,
MTBE, hexane). The added purpose of the solvents, and in particular
the miscible solvents, was to precipitate endogenous proteins from
the samples. After 3 sequential extractions with the particular
solvent, the extract layer for the aqueous samples retained >79% of
the total TCS, while the extract layer for the immiscible solvents
retained 33e82% (Fig. 1A). Interestingly, hexane, the often-used
solvent for extracting lipophilic TCS from breast milk, retained
the least amount of TCS at 33%. In some instances, co-solvents are
added, such as water-miscible acetone at 10% (Allmyr et al., 2006b)
or water-immiscible DCM at 50% (Wang et al., 2011), to change the
polarity of the solution and to drive the analyte into a particular
phase. So, to further explore if the addition of acid or adding
acetone impacted TCS recovery into the extract phase, we tested
those conditions as well, and no signiﬁcant improvement was
made (Fig. 1B). We then explored how adding a more polar water
phase would impact the TCS recovery when hexane and acetonitrile were used as co-solvents. In this case, we saw a dramatic difference, wherein with increasing amounts of water, the recovery of
TCS in the hexane extract was improved (Fig. 1C). Therefore, for the
remainder of this study, we added water (up to 80%) during the ﬁrst
hexane extraction step.
3.2.2. TCS determination in breast milk samples and method
validation
During the extraction procedure of TCS from breast milk samples, no emulsions formed in any of the samples. Emulsions are a
common issue when performing extractions of milk and similar
bioﬂuids that contain lipids (Sadtler, 1909). The addition of the
MgSO4 salt and its ability to absorb water and increase its polarity
likely reduces the amount of available water capable of emulsifying.
A matrix-matched calibration curve was completed and showed
no difference with regard to the slope, nor the intercept with the yaxis. This is particularly valuable for a study like this which reduces
i) the need for a valuable and sometimes harder to obtain material
such as breast milk or blood, as well as, ii) reducing the likelihood of
the matrix sample containing the analyte of interest to be
measured.
The method recovery for the spiked samples ranged from 105 to
119% (Table S1). The largest variation is at the lowest tested level,
which is expected when approaching the detection limit. The slight
and consistent overestimation may be due to the presence of TCS at
low levels in the donor breast milk standard, although when

Fig. 1. Partitioning of 14C-TCS in breast milk samples extracted using various solvents and methods. Each bar represents the average of duplicate samples with a standard deviation
below 10%. (A) The extraction solvents varied. (B) The hexane extraction method with added reagents of acid and acetone to more precisely follow previous methods. (C) The hexane
extraction method with added amounts of water.
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Table 2
Distributions of reported daily exposure to TCS-containing PCPs separated by participants who had detectable and non-detectable amounts of TCS in their breast milk
samples.

No daily use
Dermal use only
Oral use only
Dermal and oral use
TOTAL

Fig. 2. Distribution of triclosan concentrations (ng mL1) in the breast milk samples
(12 out of 45) with detectable amounts of TCS. The shading of each bar indicates the
type and frequency of reported exposures. Only daily exposures are presented. In all, 9
of the 12 participants reported daily use of a TCS-containing PCP.

assessed as a blank without a spike, the TCS ions were below our
detection limit.
The signal due to artifacts (area of the peak at m/z 200 and
retention time 19.4 min) in eight breast milk samples with no
detectable TCS was used to determine the instrument LOD and LOQ.
The average signal plus 3 or 10 times the standard deviation was
used to deﬁne the LOD and LOQ, respectively. This was done in
order to distinguish a real signal from noise in a sample. The lowest
point of the calibration curve was 25 ppb TCS on column, which
corresponded to 0.4 ng mL1 breast milk. This determined the
lowest quantiﬁable amount in breast milk, and therefore corresponded to the method LOQ. All samples with signals above the
instrument LOD contained TCS levels above 0.4 ng mL1 breast milk
(Fig. 3). Four of these (breast milk samples from participants 1e4)
produced signals also above the instrument LOQ.
For comparison to previously published methods for TCS
quantiﬁcation in breast milk, we report improved LOQ in contrast
to Ye et al. (1 ng mL1 with HPLC-MS/MS) (Ye et al., 2008), but not
as good as Allmyr et al. (0.018 ng g1 with GC-MS) (Allmyr et al.,
2006b).
3.2.3. TCS detection and reported TCS-containing PCP use
Of the 45 samples analyzed, 12 (27%) of them produced signals

Detected

Non-detected

3
5
2
2
12

22
5
2
4
33

above the method LOD (Fig. 2), ranging from 1 to 13.6 ng mL1
(ppb). These 12 are referred to as the ‘detectable amounts of TCS in
breast milk group’, while the remaining 33 are referred to as the
‘non-detectable amounts of TCS in breast milk group’ for the purposes of evaluating the infant fecal microbiome analyses. Of the 12
with detectable TCS levels, 75% (n ¼ 9) reported daily exposure to at
least one TCS-containing PCP intended for either dermal or oral
contact. More speciﬁcally, daily dermal exposure to a TCScontaining PCP was reported for 58% (n ¼ 7), while daily oral
exposure was reported for 33% (n ¼ 4). Only two people (17%)
indicated daily exposure to both dermal and oral products (Table 2).
Given that Cohort 2 was a year after Cohort 1, and that only one
person (9%) from Cohort 2 (n ¼ 11) had detectable amounts of TCS
compared to 12 people (32%) from Cohort 1 who had detectable
amounts of TCS, this suggests that exposure nationally is declining
as expected given the 2016 FDA guidelines for TCS (FDA, 2016),
possibly related to more informed choices, public awareness of TCS
and its potential harm, or less availability of TCS containing products. Comparing the detectable and non-detectable groups, Table 2
shows the distribution of daily exposure for dermal, oral and
dermal þ oral products. The distributions of those using products
daily are very similar (i.e., 11 from the non-detectable group,
comprised from 5 dermal, 2 oral, and 4 dermal þ oral; and 9 from
the detectable group, comprised of 5 dermal, 2 oral, and 2
dermal þ oral), however there are many more participants total in
the non-detecable group. Thus, only 33% (11 out of 33) report using
TCS-containing PCPs on a daily basis in the non-detectable group,
compared to 75% (9 out of 12) from the detectable group.
Limitations to this study include the small sample size (n ¼ 45)
and the reliance of survey results on participant recall of PCP use

Fig. 3. Boxplots of alpha diversity. By the Shannon Index, the group exposed to non-detectable levels of TCS in breast milk had signiﬁcantly greater alpha diversity than the group
exposed to detectable levels of TCS in breast milk group. There were no signiﬁcant differences in alpha diversity by the Chao1 index.
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and without additional conﬁrmation. The survey was designed to
avoid bias for or against the use of antibacterial products, although,
as with all studies using human subjects, knowledge on this subject
matter may have been obtained through media news and
marketing.
This study documents that mothers who use commercial
products that contain TCS, are more likely to have higher levels of
TCS in their breast milk than those who identify and use products
that do not contain TCS. The strength of this correlation suggests
that other known exposures from materials coated or impregnated
with TCS, such as some kitchenwares, specialized clothing, or
certain ofﬁce products, while they may cumulatively result in
elevated body burden levels, the evidence suggests that their
contributions are minor.
3.3. Infant fecal microbiome
Infant stool samples from the time point closest to the breast
milk sample used for TCS analysis were assessed for differences in
alpha diversity, beta diversity, and differential abundance in taxa
between infants fed milk containing detectable levels of TCS and
non-detectable levels of TCS. The unweighted UniFrac and generalized UniFrac (Lozupone and Knight, 2005) NMDS plots used 3
dimensions, the weighted UniFrac NMDS plot needed only 2 dimensions (Figure S2). There was no visible separation between
detectable and non-detectable stool samples on any plot. The
dispersion of samples between the two groups was signiﬁcantly
different using both unweighted UniFrac (p ¼ 0.036) and generalized UniFrac (p ¼ 0.0074), and was borderline signiﬁcant using
weighted UniFrac (p ¼ 0.054). There was no signiﬁcant difference
using PERMANOVA by any of the UniFrac measures.
In the alpha diversity analysis, the stool samples from infants fed
breast milk with detectable levels of TCS had signiﬁcantly lower
alpha diversity by the Shannon Index (p ¼ 0.025) but the Chao1
index did not differ signiﬁcantly (p ¼ 0.97) (Fig. 3). This suggests
that while exposure to breast milk containing detectable levels of
TCS did not reduce the richness (total number of OTUs) found in the
infant gut, it did result in a reduction in evenness. This suggests that
there are greater differences in the distribution of the relative
abundances of OTUs in the detectable group than the nondetectable group.
LEfSE also identiﬁed several differential abundant taxa at the
genus level and above (Fig. 4). The infants exposed to nondetectable levels of TCS in breast milk had signiﬁcantly higher
relative abundance of family Lachnospiraceae, class Erysipelotrichi,
order Erysipelotrichales, and family Erysipelotrichaceae. The

Fig. 4. LEfSE results comparing infants exposed to detectable and non-detectable
levels of TCS in breast milk. Taxa in green were signiﬁcantly enriched in infants
exposed to non-detectable levels of TCS in breast milk and taxa in red were signiﬁcantly enriched in infants exposed to detectable levels of TCS in breast milk. OTU level
differences and unidentiﬁed taxa are excluded from the plot. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the Web version of
this article.)

infants exposed to detectable levels of TCS in breast milk had
signiﬁcantly higher relative abundance of genus Dermabacter, order
Rhodospirillales, and family Rhodospirillaceae. While variations in
abundant taxa have been seen in ﬁsh exposed to TCS, the microbiome response to TCS in ﬁsh differed from what was observed in
this study. The TCS ﬁsh exhibited increased Shannon Index values
with higher triclosan exposure and also showed signiﬁcant differences between groups by PERMANOVA (Narrowe et al., 2015),
where this study found decreased Shannon Index values with TCS
exposure and no signiﬁcant differences using PERMANOVA.
Overall, the purpose of this pilot study was to gain a preliminary
appreciation of the connectivity between TCS exposure from breast
milk and subsequent infant fecal microbiome diversity. We recognize that TCS is not the only exogenous chemical in breast milk
(LaKind et al., 2004) and that endogenous components are also
variable and inﬂuence the infant fecal microbiome (Ballard and
Morrow, 2013). Nonetheless, although this study was a single
location with a small sample size (n ¼ 12), the evidence of an
altered fecal microbiome along with TCS detected in the breast milk
fed to that individual is larger than the inherent variability that
might have been observed by chance alone. Furthermore, the
functional consequences of the changes in the infant gut microbiome described here remain unclear. For example, while infants
are known to be colonized with Lachnospiraceae, the role of
Lachnospiraceae in the infant gut remains unclear (Sagheddu et al.,
2016).
This study examined infants ranging from 8 to 13 weeks (~2e3
months old) who were fed exclusively breast milk. Ingestion of TCS
from breast milk may not be the only source of exposure to an
infant. Chemicals could be transferred to the infant via sucking on
hands, paciﬁers, bottle nipples, and clothing/fabrics (Ginsberg and
Balk, 2016). In this study, we did not include dishwashing liquids,
of which a few formulations do contain TCS and could have left
residues on paciﬁers and bottles (Tsai et al., 2008). If breast pump
parts used to collect milk for this study were washed similarly, the
contaminating TCS might have appeared in the breast milk analysis,
and if it were present on bottles used for the infant, would still have
resulted in exposure to the infant. Due of the rapid nature of TCS
removal from the body, an ideal follow-up study would be to
request mothers using TCS-containing PCPs to stop use for a set
amount of time and to observe the changes in their breast milk
concentrations and the impact (potentially short-term or longterm) on their infant's fecal microbiome.
4. Conclusion
The developing infant microbiome is particularly sensitive to
modulation from environmental factors including diet, mode of
delivery and antibiotic use, among others (Blaser and DominguezBello, 2016). The outcomes of this study document that the bacterial diversity in the fecal microbiome of the infants exposed to
breast milk containing detectable levels of TCS differed compared
to their peers who were exposed to breast milk containing nondetectable levels of TCS. This study demonstrates that exogenous
chemicals are correlated with altering microbiome diversity in the
early developing infant intestinal community. Human health is
increasingly associated with the successful development of the
microbial communities within humans and more speciﬁcally on
microbiome functionality. Given the increasingly important role
the establishment of a healthy infant gut microbiome has to healthy
phenotypes later in life (Charbonneau et al., 2016), understanding
how environmentally-acquired antimicrobials such as TCS inﬂuence infant gut development is critical to identify and rectify
problematic shifts in infant gut health. This study demonstrated
that reported daily use of TCS-containing PCPs correlates with
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measured exposure levels. The implications of these exposures to
microbial communities should now be considered when developing, marketing, and regulating chemicals that alter the microbial
communities important to human health. Additional ﬁndings from
this work deliver better methods for extracting TCS including i)
increasing salt to eliminate emulsion formation and ii) increasing
water as a solvent to drive more TCS into the hexane extract.
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